Related Experiment Video
Updated: May 11, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
24.1K
Biosensor-based multiple cross displacement amplification platform for visual and rapid identification of hepatitis C
Xu Chen1,2,3, Shilei Dong4, Yuanfang Shi1
1The Second Clinical Medical College, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, People's Republic of China.
Journal of Medical Virology
|March 1, 2024
Summary
A new diagnostic assay, reverse transcription multiple cross displacement amplification integrated with a gold-nanoparticle-based lateral flow biosensor (RT-MCDA-AuNPs-LFB), offers rapid and sensitive detection of Hepatitis C Virus (HCV). This point-of-care tool can identify major HCV genotypes within 35 minutes, aiding early diagnosis.
Area of Science:
- Molecular Diagnostics
- Biotechnology
- Virology
Background:
- Hepatitis C Virus (HCV) infection poses a significant global health challenge, particularly in resource-limited settings.
- Early detection and prompt treatment are crucial for managing HCV and preventing disease progression.
- Existing diagnostic methods may lack the speed, sensitivity, or accessibility required for effective point-of-care (POC) screening.
Purpose of the Study:
- To develop and validate a novel, rapid, sensitive, and specific molecular diagnostic assay for Hepatitis C Virus (HCV) detection.
- To establish a point-of-care (POC) diagnostic platform for visual identification of HCV.
- To evaluate the performance of the assay for major prevalent HCV genotypes.
Main Methods:
- Development of a reverse transcription multiple cross displacement amplification (RT-MCDA) assay targeting the 5' untranslated region of HCV.
- Integration of the RT-MCDA assay with a gold-nanoparticle-based lateral flow biosensor (AuNPs-LFB) for visual detection.
- Optimization of reaction conditions (temperature and time) and assessment of assay sensitivity and specificity.
Main Results:
- The developed RT-MCDA-AuNPs-LFB assay achieved a limit of detection of 10 copies per test with 100% specificity for tested HCV strains.
- Optimal reaction conditions were determined as 68°C for 25 minutes for RT-MCDA.
- The entire assay procedure, including sample preparation, amplification, and visual detection, was completed in under 35 minutes.
Conclusions:
- The novel HCV-RT-MCDA-AuNPs-LFB assay provides a rapid, sensitive, specific, visual, and cost-effective method for HCV detection.
- This assay demonstrates significant potential as a point-of-care diagnostic platform for field screening and early clinical detection of HCV infection.
- The assay's ability to detect multiple prevalent HCV genotypes contributes to its utility in diverse geographical settings.
